BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 932 filers reported holding BAXTER INTL INC in Q1 2023. The put-call ratio across all filers is 0.56 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $59,490,745 | +38.1% | 1,305,767 | +22.9% | 2.76% | +9.5% |
| Q1 2023 | $43,089,281 | -10.1% | 1,062,359 | +78.3% | 2.52% | -18.3% |
| Q3 2020 | $47,910,000 | +38.9% | 595,745 | +48.7% | 3.09% | +44.4% |
| Q2 2020 | $34,487,000 | -41.9% | 400,545 | -45.2% | 2.14% | -57.4% |
| Q1 2020 | $59,336,000 | +27.1% | 730,830 | +30.9% | 5.02% | +45.1% |
| Q4 2019 | $46,683,000 | +30.3% | 558,280 | +36.3% | 3.46% | +14.5% |
| Q3 2019 | $35,821,000 | +4.0% | 409,525 | -2.6% | 3.02% | +18.8% |
| Q2 2019 | $34,439,000 | +103.0% | 420,505 | +101.6% | 2.54% | +92.0% |
| Q1 2019 | $16,963,000 | +259.1% | 208,625 | +225.0% | 1.32% | +72.5% |
| Q1 2014 | $4,724,000 | – | 64,200 | – | 0.77% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |